Protagonist: Đã nộp đơn đăng ký EMA cho icotrokinra trong bệnh vảy nến mảng

Trích đoạn nguồn

EX-99.1 2 tm2530353d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67 th Annual American Society of Hematology (ASH) meeting in December First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist IND-enabling studies progressing as planned with triple-GLP/GIP/GCG ag

SEC 8-K

Thêm về tài sản này

Mang tính quyết định

18 thg 3, 2026

11:49

JNJJohnson & Johnson

JNJ: FDA phê duyệt ICOTYDE (icotrokinra) cho bệnh vảy nến mảng vừa đến nặng

FDA phê duyệtThông cáo báo chí của công tyMở hồ sơ

Mang tính quyết định

17 thg 3, 2026

00:00

PTGXProtagonist

Protagonist Therapeutics, Inc · FDA phê duyệt Icotyde (icotrokinra)

FDA phê duyệtDanh sách phê duyệt thuốc mới FDAMở hồ sơ